PMC:7784786 / 3908-4157
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 150 | 210-218 | Species | denotes | patients | Tax:9606 |
| 154 | 100-110 | Chemical | denotes | itolizumab | MESH:C000597346 |
| 157 | 201-209 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T35 | 0-249 | Sentence | denotes | On account of its well proven effect on T-cell activation and proinflammatory cytokines production, itolizumab was included as part of a Cuban expanded access protocol in critical, severe and moderate COVID-19 patients with high risk of aggravation. |